Medical equipment manufacturer Tissue Regenix has halted trading of its shares on London’s Alternative Investment Market as it works to clarify its financial position.
The company’s value had fallen sharply before the suspension, with its market capitalisation dropping to around £5 million after a 70% share price decline in a month. The decision follows major revisions to the financial statements, which reversed previously reported profits into losses.
The firm restated its 2024 results from a $1.9 million profit to a $1 million loss. Interim results for the first half of 2025 were also adjusted from a $0.2 million profit to a $2.3 million loss, driven by a reassessment of inventory and cost of sales.
Tissue Regenix has seen several senior management changes in recent months. Its former CEO, Daniel Lee, left the business shortly before the revisions were announced, and its long-time CFO, David Cocke, retired in August. Executive chairman Jay LeCoque has since taken on the role of acting chief executive, while former group finance director Kirsten Lund has stepped in as CFO.
The new leadership team is now assessing the restated figures, the company’s cash position, and future performance outlook. Cost-cutting measures worth at least $2 million are under review as part of a broader restructuring plan.
